PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32752938-7	2021	Similar analysis with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies.	Ergotamine	64-74	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	22-26
15224175-0	2004	5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs.	Ergotamine	125-135	5-hydroxytryptamine receptor 1B	Canis lupus familiaris	0-6
32078320-0	2020	Binding interactions of ergotamine and dihydroergotamine to 5-hydroxytryptamine receptor 1B (5-HT1b) using Molecular Dynamics Simulations and Dynamic Network Analysis.	Ergotamine	24-34	5-hydroxytryptamine receptor 1B	Homo sapiens	93-99
30695640-9	2019	These findings imply that prejunctional 5-HT1B/1D, D2-like, and alpha2-adrenergic receptors mediate the sensory inhibition induced by 0.31 mug of ergotamine kg-1 min-1, whereas larger doses may involve other receptors.	Ergotamine	146-156	5-hydroxytryptamine receptor 1B	Rattus norvegicus	40-46
27068146-0	2016	Role of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine and valerenic acid in the rat formalin test.	Ergotamine	74-84	5-hydroxytryptamine receptor 1B	Rattus norvegicus	19-25
27068146-2	2016	This study set out to investigate the pharmacological profile of the antinociception produced by intrathecal and intraplantar administration of ergotamine (a 5-HT1B/1D and 5-HT5A/5B receptor agonist) and valerenic acid (a partial agonist at 5-HT5A receptors).	Ergotamine	144-154	5-hydroxytryptamine receptor 1B	Rattus norvegicus	158-164
27068146-8	2016	Our results suggest that ergotamine and valerenic acid produce antinociception via 5-HT5A and 5-HT1B/1D receptors located at both spinal and peripheral sites.	Ergotamine	25-35	5-hydroxytryptamine receptor 1B	Rattus norvegicus	94-100
26978043-7	2016	Our structure prediction and ligand docking protocol was especially successful in the case of 5-HT1B and 5-HT2B-ergotamine complexes for which we provide one of the most accurate predictions.	Ergotamine	112-122	5-hydroxytryptamine receptor 1B	Homo sapiens	94-100
26978043-7	2016	Our structure prediction and ligand docking protocol was especially successful in the case of 5-HT1B and 5-HT2B-ergotamine complexes for which we provide one of the most accurate predictions.	Ergotamine	112-122	5-hydroxytryptamine receptor 2B	Homo sapiens	105-111
25601315-4	2015	Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine bound.	Ergotamine	148-158	5-hydroxytryptamine receptor 1B	Homo sapiens	75-81
25601315-4	2015	Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine bound.	Ergotamine	148-158	5-hydroxytryptamine receptor 2B	Homo sapiens	86-92
25313636-2	2014	Publication of the X-ray crystal structure of serotonergic 5-HT1B and 5-HT2B receptors in complex with ergotamine, a drug capable of activating G protein coupling and beta-arrestin signaling at the 5-HT1B receptor but clearly favoring beta-arrestin over G protein coupling at the 5-HT2B subtype, has recently provided structural insight into this phenomenon.	Ergotamine	103-113	5-hydroxytryptamine receptor 2B	Homo sapiens	70-76
25313636-2	2014	Publication of the X-ray crystal structure of serotonergic 5-HT1B and 5-HT2B receptors in complex with ergotamine, a drug capable of activating G protein coupling and beta-arrestin signaling at the 5-HT1B receptor but clearly favoring beta-arrestin over G protein coupling at the 5-HT2B subtype, has recently provided structural insight into this phenomenon.	Ergotamine	103-113	5-hydroxytryptamine receptor 2B	Homo sapiens	280-286
24899801-8	2014	A virtual screening approach coupled with docking energies and druglikeness rules illustrated that ergotamine and PB-414901692 are potential inhibitor compounds for targeting KCNK18.	Ergotamine	99-109	potassium two pore domain channel subfamily K member 18	Homo sapiens	175-181
24531557-3	2014	Ergotamine, typically used to treat migraine, has less than 5% bioavailability due to extensive first-pass metabolism by cytochrome P450 3A4 (CYP3A4).	Ergotamine	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-140
24531557-3	2014	Ergotamine, typically used to treat migraine, has less than 5% bioavailability due to extensive first-pass metabolism by cytochrome P450 3A4 (CYP3A4).	Ergotamine	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
23519210-2	2013	We report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.	Ergotamine	126-136	5-hydroxytryptamine receptor 1B	Homo sapiens	46-52
23519215-2	2013	We report biochemical studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ERG), and related ergolines display strong functional selectivity for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at the 5-HT1B receptor.	Ergotamine	102-112	5-hydroxytryptamine receptor 1B	Homo sapiens	303-309
23519215-2	2013	We report biochemical studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ERG), and related ergolines display strong functional selectivity for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at the 5-HT1B receptor.	Ergotamine	114-117	5-hydroxytryptamine receptor 1B	Homo sapiens	303-309
19232578-1	2009	BACKGROUND: Cabergoline is an ergotamine derivative that increases the expression of glial cell line-derived neurotrophic factor (GDNF) in vitro.	Ergotamine	30-40	glial cell derived neurotrophic factor	Rattus norvegicus	85-128
19232578-1	2009	BACKGROUND: Cabergoline is an ergotamine derivative that increases the expression of glial cell line-derived neurotrophic factor (GDNF) in vitro.	Ergotamine	30-40	glial cell derived neurotrophic factor	Rattus norvegicus	130-134
32661494-5	2020	Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.	Ergotamine	0-10	vitronectin	Homo sapiens	105-114
32661494-5	2020	Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.	Ergotamine	0-10	angiotensin converting enzyme 2	Homo sapiens	126-131
25712664-4	2015	In line with the recent data, activation of 5-HT2B receptor by ergot derivatives i.e. ergotamine, methysergide, pergolide, and carbegoline is involved in pathogenesis of drug-induced valvulopathy.	Ergotamine	86-96	5-hydroxytryptamine receptor 2B	Homo sapiens	44-59
25815288-3	2015	The first experiment validated the effects of ergot alkaloids [0, 20, and 40 muM of ergotamine (ET), dihydroergotamine (DHET), and ergonovine (EN)] on human CYP3A4 using the P450-Glo assay (Promega  V9800).	Ergotamine	84-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
24975101-0	2014	Pharmacological evidence that 5-HT1A/1B/1D, alpha2-adrenoceptors and D2-like receptors mediate ergotamine-induced inhibition of the vasopressor sympathetic outflow in pithed rats.	Ergotamine	95-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
24975101-11	2014	The above results suggest that ergotamine induces inhibition of the vasopressor sympathetic outflow by activation of prejunctional 5-HT1A, 5-HT1B/1D, alpha2-adrenoceptors and D2-like receptors in pithed rats.	Ergotamine	31-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-137
24975101-11	2014	The above results suggest that ergotamine induces inhibition of the vasopressor sympathetic outflow by activation of prejunctional 5-HT1A, 5-HT1B/1D, alpha2-adrenoceptors and D2-like receptors in pithed rats.	Ergotamine	31-41	5-hydroxytryptamine receptor 1B	Rattus norvegicus	139-145
25030302-3	2014	The GPCR Dock 2013 assessment, in which researchers were challenged to predict the crystallographic structures of serotonin 5-HT(1B) and 5-HT(2B) receptors bound to ergotamine, provided an excellent opportunity to benchmark the current state of this field.	Ergotamine	165-175	5-hydroxytryptamine receptor 1B	Homo sapiens	124-131
25030302-3	2014	The GPCR Dock 2013 assessment, in which researchers were challenged to predict the crystallographic structures of serotonin 5-HT(1B) and 5-HT(2B) receptors bound to ergotamine, provided an excellent opportunity to benchmark the current state of this field.	Ergotamine	165-175	5-hydroxytryptamine receptor 2B	Homo sapiens	137-144
25030302-4	2014	Our contributions to GPCR Dock 2013 accurately predicted the binding mode of ergotamine with RMSDs below 1.8 A for both receptors, which included the best submissions for the 5-HT(1B) complex.	Ergotamine	77-87	5-hydroxytryptamine receptor 1B	Homo sapiens	175-182
15224175-1	2004	It has previously been suggested that ergotamine produces external carotid vasoconstriction in vagosympathectomised dogs via 5-HT1B/1D receptors and alpha2-adrenoceptors.	Ergotamine	38-48	5-hydroxytryptamine receptor 1B	Canis lupus familiaris	125-131
15224175-9	2004	Thus, the cranio-selective vasoconstriction elicited by ergotamine in dogs is predominantly mediated by 5-HT1B receptors as well as alpha2A/2C-adrenoceptor subtypes and, to a lesser extent, by alpha1-adrenoceptors.	Ergotamine	56-66	5-hydroxytryptamine receptor 1B	Canis lupus familiaris	104-110
12781836-0	2003	Effect of ergotamine on plasma metabolite and insulin-like growth factor-1 concentrations in cows.	Ergotamine	10-20	insulin like growth factor 1	Bos taurus	46-74
12781836-1	2003	Bovine plasma was assayed to determine if ergotamine affected plasma metabolite and insulin-like growth factor-1 (IGF-1) concentrations.	Ergotamine	42-52	insulin like growth factor 1	Bos taurus	84-112
12781836-1	2003	Bovine plasma was assayed to determine if ergotamine affected plasma metabolite and insulin-like growth factor-1 (IGF-1) concentrations.	Ergotamine	42-52	insulin like growth factor 1	Bos taurus	114-119
12781836-7	2003	Plasma IGF-1 decreased in response to ergotamine.	Ergotamine	38-48	insulin like growth factor 1	Bos taurus	7-12
12781836-14	2003	Plasma IGF-1 decreased after ergotamine treatment.	Ergotamine	29-39	insulin like growth factor 1	Bos taurus	7-12
12781836-16	2003	Results indicated ergotamine altered plasma metabolite and IGF-1 concentrations in cows.	Ergotamine	18-28	insulin like growth factor 1	Bos taurus	59-64
12558771-3	2003	Ergotamine and dihydroergotamine are highly potent at the 5-HT1B and 5-HT1D antimigraine receptors and, as a consequence, the plasma concentrations that are necessary to produce the appropriate therapeutic and physiologic effects are very low.	Ergotamine	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	58-64
12558771-3	2003	Ergotamine and dihydroergotamine are highly potent at the 5-HT1B and 5-HT1D antimigraine receptors and, as a consequence, the plasma concentrations that are necessary to produce the appropriate therapeutic and physiologic effects are very low.	Ergotamine	0-10	5-hydroxytryptamine receptor 1D	Homo sapiens	69-75
11518230-4	2001	Contractile responses to ergovaline and ergotamine were surmountably antagonized by the 5-HT2A receptor antagonist ketanserin (3 nM).	Ergotamine	40-50	5-hydroxytryptamine receptor 2A	Rattus norvegicus	88-94
12046966-11	2002	Both breeds responded to ergotamine with increased (p < 0.01) plasma cortisol, glucagon, and glucose and reduced (p < 0.01) insulin concentrations.	Ergotamine	25-35	insulin	Bos taurus	130-137
11044256-11	2000	The circulating Hp, TNF-alpha, and TXB(2) increases were blunted by pretreatment with ET compared with ET + LPS.	Ergotamine	86-88	tumor necrosis factor	Bos taurus	20-29
11104741-7	2000	(+/-)-, (+)-, and (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT(2B) receptor and were partial to full agonists at the 5-HT(2B) receptor.	Ergotamine	39-49	5-hydroxytryptamine receptor 2B	Homo sapiens	142-159
11104741-7	2000	(+/-)-, (+)-, and (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT(2B) receptor and were partial to full agonists at the 5-HT(2B) receptor.	Ergotamine	39-49	5-hydroxytryptamine receptor 2B	Homo sapiens	201-218
11044256-12	2000	Ergotamine by itself increased circulating cortisol and RT, whereas it decreased serum prolactin (PRL).	Ergotamine	0-10	prolactin	Bos taurus	87-96
10764077-0	2000	Ergotamine alters plasma concentrations of glucagon, insulin, cortisol, and triiodothyronine in cows.	Ergotamine	0-10	insulin	Bos taurus	53-60
10816333-6	2000	In the presence of ergotamine, the contractile response to noradrenaline was completely blocked not only in control animals, but also in animals treated with ANG II alone or in combination with minoxidil.	Ergotamine	19-29	angiotensinogen	Rattus norvegicus	158-164
10764077-1	2000	Bovine plasma was assayed to determine whether ergotamine, an ergopeptide isolated from endophytic tall fescue, affected cortisol, triiodothyronine, insulin, and glucagon concentrations.	Ergotamine	47-57	insulin	Bos taurus	149-156
10764077-22	2000	Insulin was decreased (P < .01) and glucagon increased (P < .01) within 1 h after ergotamine treatment, but they were not altered by saline.	Ergotamine	88-98	insulin	Bos taurus	0-7
10522646-9	1999	Ergotamine treatment significantly increased IL-6 levels at the 2.0 mg/kg dose and greater and TNF-alpha at the highest dose.	Ergotamine	0-10	interleukin 6	Mus musculus	45-49
10682812-12	2000	Ergotamine decreased plasma (P < .01) prolactin and increased (P < .01) cortisol concentrations in both breeds, despite some breed variation.	Ergotamine	0-10	prolactin	Bos taurus	41-50
10522646-12	1999	Ergotamine affected the proinflammatory cytokine IL-6, and this increase may contribute to fescue tosicosis.	Ergotamine	0-10	interleukin 6	Mus musculus	49-53
8397071-3	1993	This was carried out by assay of the thrombin-stimulated generation of inositol phosphates in platelets from 12 migraine patients with chronic daily headache and analgesic misuse, 7 migraine patients with chronic daily headache and ergotamine misuse and 7 control subjects.	Ergotamine	232-242	coagulation factor II, thrombin	Homo sapiens	37-45
10328360-4	1999	Ergovaline and ergotamine tartrate were equally effective in inhibiting vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production, with consistent nanomolar effective concentration (EC50) values.	Ergotamine	15-34	vasoactive intestinal peptide	Rattus norvegicus	103-106
10328360-7	1999	Our results indicate that the commercially available ergot alkaloids ergotamine tartrate and ergonovine may be used interchangeably in the D2 dopamine receptor system to simulate the effects of extracted ergovaline and ergine and to examine responses in receptor binding and the inhibition of cyclic AMP.	Ergotamine	69-88	dopamine receptor D2	Rattus norvegicus	139-159
9778659-1	1998	In the rat dorsal hippocampus and dorsal raphe nucleus, the microiontophoretic application of ergotamine and 5-HT suppressed the firing activity of CA3 pyramidal neurons and 5-HT neurons, an effect antagonized by selective 5-HT1A receptor antagonists.	Ergotamine	94-104	carbonic anhydrase 3	Rattus norvegicus	148-151
9778659-1	1998	In the rat dorsal hippocampus and dorsal raphe nucleus, the microiontophoretic application of ergotamine and 5-HT suppressed the firing activity of CA3 pyramidal neurons and 5-HT neurons, an effect antagonized by selective 5-HT1A receptor antagonists.	Ergotamine	94-104	5-hydroxytryptamine receptor 1A	Homo sapiens	223-238
9778659-2	1998	Co-application of ergotamine prevented the inhibitory action of 5-HT on the firing activity of CA3 pyramidal neurons but not of 5-HT neurons, indicating that ergotamine acted as a partial 5-HT1A receptor agonist in the dorsal hippocampus and as a full agonist at 5-HT1A autoreceptors.	Ergotamine	18-28	carbonic anhydrase 3	Homo sapiens	95-98
9778659-2	1998	Co-application of ergotamine prevented the inhibitory action of 5-HT on the firing activity of CA3 pyramidal neurons but not of 5-HT neurons, indicating that ergotamine acted as a partial 5-HT1A receptor agonist in the dorsal hippocampus and as a full agonist at 5-HT1A autoreceptors.	Ergotamine	158-168	carbonic anhydrase 3	Homo sapiens	95-98
9778659-2	1998	Co-application of ergotamine prevented the inhibitory action of 5-HT on the firing activity of CA3 pyramidal neurons but not of 5-HT neurons, indicating that ergotamine acted as a partial 5-HT1A receptor agonist in the dorsal hippocampus and as a full agonist at 5-HT1A autoreceptors.	Ergotamine	158-168	5-hydroxytryptamine receptor 1A	Homo sapiens	188-203
9778659-2	1998	Co-application of ergotamine prevented the inhibitory action of 5-HT on the firing activity of CA3 pyramidal neurons but not of 5-HT neurons, indicating that ergotamine acted as a partial 5-HT1A receptor agonist in the dorsal hippocampus and as a full agonist at 5-HT1A autoreceptors.	Ergotamine	158-168	5-hydroxytryptamine receptor 1A	Homo sapiens	188-194
9778659-4	1998	Although body temperature in humans remained unchanged following inhaled ergotamine, in the rat, subcutaneously injected ergotamine produced a hypothermia that was prevented by a pretreatment with the 5-HT1A/1B receptor/beta-adrenoceptor antagonist pindolol.	Ergotamine	121-131	5-hydroxytryptamine receptor 1A	Homo sapiens	201-207
9778659-5	1998	Finally in humans, ergotamine did not alter prolactin or adrenocorticotropic hormone levels, but increased growth hormone level, which was prevented by pindolol.	Ergotamine	19-29	growth hormone 1	Homo sapiens	107-121
9778659-7	1998	In conclusion, the present results suggest that ergotamine acted in the rat brain as a 5-HT1A receptor agonist and as an agonist of terminal 5-HT autoreceptor of a yet undefined subtype.	Ergotamine	48-58	5-hydroxytryptamine receptor 1A	Homo sapiens	87-102
9778659-8	1998	In humans, ergotamine also displayed some 5-HT1A receptor activity but, probably because of lack of receptor selectivity, it did not present the same profile as other 5-HT1A receptor agonists.	Ergotamine	11-21	5-hydroxytryptamine receptor 1A	Homo sapiens	42-57
9605061-2	1998	Ergotamine produced a 27% reduction in hyperemic MBF (2.62 +/- 0.11 vs 3.72 +/- 1.05 ml x min(-1) x g(-1); p <0.05), a 31% reduction in the coronary vasodilator reserve (1.81 +/- 0.50 vs 2.71 +/- 1.15; p <0.01), and a 55% increase in minimal coronary resistance (42.2 +/- 15 vs 26.7 +/- 8 mm Hg x min x ml(-1) x g(-1); p <0.001), suggesting vasoconstriction of the coronary microcirculation.	Ergotamine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	90-96
9605562-3	1998	The present study was devoted to establish the contribution of 5-HT1B/1D receptors in the constriction of AVAs elicited by 5-HT (in presence of 0.5 mg kg(-1) ketanserin), ergotamine and dihydroergotamine in anaesthetized pigs.	Ergotamine	171-181	5-hydroxytryptamine receptor 1B	Sus scrofa	63-69
9613443-4	1998	Ergotamine (EG) was conjugated to bovine serum albumin (BSA) and cholera toxin subunit B (CTB) by the Mannich reaction.	Ergotamine	0-10	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	90-93
9613443-4	1998	Ergotamine (EG) was conjugated to bovine serum albumin (BSA) and cholera toxin subunit B (CTB) by the Mannich reaction.	Ergotamine	12-14	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	90-93
9613443-11	1998	Weight gains were increased in the BSA-EG and CTB-EG groups and tended to be increased in the MoAB group vs. the unvaccinated EI group.	Ergotamine	50-52	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	46-49
7665369-3	1995	Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	Ergotamine	153-163	vasoactive intestinal peptide	Rattus norvegicus	50-53
7928330-3	1994	The clinical effective dose of ergotamine, beginning from the minimal dose of 1 mg, correlates well with its affinity for 5-HT1B and 5-HT1D receptors, and the rank order of clinical potency of ergotamine is superior to sumatriptan.	Ergotamine	31-41	5-hydroxytryptamine receptor 1B	Homo sapiens	122-128
7672873-1	1994	The double-label flow cytometric analysis of peripheral serotonergic pathways of migraine and cluster headache on a monocyte model has been used to evaluate the activity of drugs with a selective activity on central vascular 5-HT1D receptors, such as sumatriptan, ergotamine and ondansetron.	Ergotamine	264-274	5-hydroxytryptamine receptor 1D	Homo sapiens	225-231
10463349-4	1999	Sumatriptan, a specific serotonin (5-HT)1B/D agonist is used when attacks do not respond to ergotamine, or when intolerable side effects occur.	Ergotamine	92-102	5-hydroxytryptamine receptor 1B	Homo sapiens	35-42
9078499-11	1997	Ergotamine reduced (P < .01) plasma concentrations of prolactin and LH throughout the 120-min period after treatment compared with concentrations before ergotamine treatment and after saline treatment.	Ergotamine	0-10	prolactin	Bos taurus	57-66
8886417-7	1996	The relaxation to both ergotamine and 5-HT was associated with an increase in cyclic GMP.	Ergotamine	23-33	5'-nucleotidase, cytosolic II	Homo sapiens	85-88
8242725-0	1993	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?	Ergotamine	88-98	dopamine receptor D2	Homo sapiens	0-20
1513320-7	1992	The rank order of potency of ligands to compete for the [3H]5-HT-labeled site best matched the binding profile of the pharmacologically defined 5-HT1E binding site, 5-HT greater than methysergide greater than ergotamine greater than 8-hydroxy-2-(di-n-propylamino)tetralin greater than 5-carboxyamidotryptamine greater than ketanserin.	Ergotamine	209-219	5-hydroxytryptamine receptor 1E	Homo sapiens	144-150
7682702-3	1993	Saturable binding of 125I-labeled (+)-lysergic acid diethylamide to transiently expressed MR22 in COS-M6 cells was inhibited by ergotamine > methiothepin > 5-carboxamidotryptamine > 5-HT.	Ergotamine	128-138	5-hydroxytryptamine (serotonin) receptor 5B	Rattus norvegicus	90-94
7682702-4	1993	For REC17, the rank of potency was ergotamine > 5-carboxamidotryptamine > methiothepin > methysergide > 5-HT.	Ergotamine	35-45	5-hydroxytryptamine (serotonin) receptor 5B	Rattus norvegicus	4-9
6735611-6	1984	A practically insuperable obstacle is rearrangement of ergotamine under the experimental conditions, forming a stereoisomer by inversion at the C-8 position.	Ergotamine	55-65	homeobox C8	Homo sapiens	144-147
34803446-9	2021	MM/GBSA calculations from MD simulations showed that eltrombopag, glimepiride, sitagliptin, dutasteride, and ergotamine stably and strongly bind to NRP1.	Ergotamine	109-119	neuropilin 1	Homo sapiens	148-152
3917386-3	1985	In contrast, ergotamine was quickly absorbed (t1/2 = 3 min) and plasma levels (measured by HPLC) declined, with a biologic t1/2 of 2.5 hr.	Ergotamine	13-23	CD5 molecule	Homo sapiens	123-134
2664084-3	1989	One of these sites demonstrated high affinity for 5-carboxyamidotryptamine (5-CT) and ergotamine, consistent with the known pharmacology of the 5-HT1D receptor; the second site demonstrated low affinity for 5-CT and ergotamine.	Ergotamine	86-96	5-hydroxytryptamine receptor 1D	Homo sapiens	144-150
2664084-3	1989	One of these sites demonstrated high affinity for 5-carboxyamidotryptamine (5-CT) and ergotamine, consistent with the known pharmacology of the 5-HT1D receptor; the second site demonstrated low affinity for 5-CT and ergotamine.	Ergotamine	216-226	5-hydroxytryptamine receptor 1D	Homo sapiens	144-150
2664084-7	1989	Competition studies with nonradioactive drugs indicated that, of the drugs tested, 5-CT and ergotamine displayed the highest selectivity for the 5-HT1D site versus the 5-HT1E site.	Ergotamine	92-102	5-hydroxytryptamine receptor 1D	Homo sapiens	145-151
2664084-7	1989	Competition studies with nonradioactive drugs indicated that, of the drugs tested, 5-CT and ergotamine displayed the highest selectivity for the 5-HT1D site versus the 5-HT1E site.	Ergotamine	92-102	5-hydroxytryptamine receptor 1E	Homo sapiens	168-174
20488103-2	1984	We report here that certain ergot derivatives of the ergopeptine class, such as bromocriptine, ergotamine and codergocrine known to interact with alpha-adrenergic receptors, will also potentiate the effects of VIP on cyclic-AMP levels, without increasing directly the levels of the cyclic nucleotide.	Ergotamine	95-105	vasoactive intestinal polypeptide	Mus musculus	210-213
7430884-4	1980	In contrast, ergotamine reduced secretion of both GH and prolactin and considerably inhibited the growth of the tumour.	Ergotamine	13-23	gonadotropin releasing hormone receptor	Rattus norvegicus	50-52
1126359-6	1975	The response to ACh was affected in accordance with the prediction of an action of ACh and ergotamine on different receptors.	Ergotamine	91-101	acyl-CoA thioesterase 12	Rattus norvegicus	16-19
33419260-3	2020	We performed molecular dynamics simulations with known beta-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region.	Ergotamine	120-130	5-hydroxytryptamine receptor 2B	Homo sapiens	151-166